Childhood Cancer Therapies Linked to Adult Obesity

Article

Childhood cancer patients treated with brain irradiation may be at a higher risk for developing into obese adults, according to a new study.

Image © sunabesyou / Shutterstock.com

Childhood cancer patients treated with brain irradiation or chemotherapy with glucocorticoids may be at a higher risk for developing into obese adults. According to a new study published in Cancer, of the 1,996 individuals included in the analysis who were treated for and survived a childhood cancer, 36.2% had a body mass index (BMI) ≥ 30 km/m2, which qualifies as obese. This proportion was 14% greater than the prevalence seen in the general US population.

“The high prevalence of obesity in cancer survivors is of great concern and underscores the need to develop more effective counseling and weight loss interventions for this growing population,” said study author Carmen Wilson, BSc, PhD, of the department of epidemiology and cancer control at St. Jude Children’s Research Hospital in Memphis, in a statement.

The strongest factor related to adulthood obesity among survivors was obesity in childhood-a factor that is also strong for predicting adulthood obesity in the general US population. Childhood cancer survivors who were obese when diagnosed were almost five times more likely to be obese in adulthood compared with the other survivors included in the analysis.

Prior studies showed that childhood cancer survivors who were treated with cranial radiation had higher rates of obesity compared with the population at large. Brain irradiation was previously used to treat brain tumors in some pediatric patients, but is now no longer used to treat patients with acute lymphoblastic leukemia at St. Jude.

The study, conducted by Wilson, Kirsten Ness, PhD, also of the department of epidemiology and cancer control at St. Jude, and colleagues, included individuals treated at St. Jude who were diagnosed 10 or more years ago. The median age at diagnosis was 7.2 years and the median follow-up was 32.4 years.

The findings may help identify cancer survivors at highest risk of obesity based on clinical and treatment risk factors, said Wilson in a statement.

Wilson noted that the findings could provide a foundation for future research efforts aimed at characterizing molecular pathways involved in the link between childhood cancer treatment and obesity. “Also, the ability to identify patients at increased risk may guide selection of therapeutic protocols that will maximize treatment outcomes while simultaneously minimizing the risk of long-term complications among children diagnosed with cancer,” said Ness.

Forty-seven percent of the childhood cancer survivors who had cranial radiation as part of their treatment were obese compared with 29.4% of the survivors who did not receive cranial radiation. The chance of being obese as adults increased further in those who also received glucocorticoids (P = .014) and who were diagnosed with cancer at a younger age (P = .013).

Survivors who were treated with abdominal or pelvic radiation were 50% less likely to be obese in adulthood (P < .0001).

Data on cancer survivors’ diets, exercise, and other lifestyle factors that may influence obesity were not available to the study authors.

Assessing genetic risk factors, the authors also identified variations in four chromosomal regions that were linked with a higher chance of obesity following brain irradiation. All four regions were in close proximity to genes implicated in neuronal growth, repair, and connectivity.

Although these genetic results need to be further investigated, they suggest that these neuronal function genes “may modify the risk of obesity in childhood cancer survivors treated with cranial irradiation,” Wilson said in a statement. “Understanding the genetic basis of why certain survivors are more vulnerable to treatment-induced health problems may help us identify high-risk patients and develop strategies to reduce or better manage their risk.”

Recent Videos
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
The phase 3 Gliofocus trial aims to meaningfully improve survival and quality of life with niraparib among patients with newly diagnosed glioblastoma.
Findings from a proof-of-concept study show a potential survival benefit with niraparib/radiotherapy in patients with newly diagnosed glioblastoma.
ZAP-X may provide submillimeter accuracy when administering radiation to patients with brain tumors.